STERIS (STE) Projected to Post Quarterly Earnings on Wednesday

STERIS (NYSE:STE) is expected to be announcing its Q3 2026 results after the market closes on Wednesday, February 4th. Analysts expect the company to announce earnings of $2.53 per share and revenue of $1.4812 billion for the quarter. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earning report page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the firm earned $2.14 earnings per share. On average, analysts expect STERIS to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

STERIS Stock Performance

NYSE STE opened at $262.81 on Monday. The firm has a market cap of $25.79 billion, a P/E ratio of 37.76 and a beta of 1.03. STERIS has a 52-week low of $204.90 and a 52-week high of $269.44. The business’s 50-day moving average price is $259.30 and its 200 day moving average price is $248.90. The company has a quick ratio of 1.63, a current ratio of 2.37 and a debt-to-equity ratio of 0.27.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, February 17th. STERIS’s dividend payout ratio (DPR) is 36.21%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

Insiders Place Their Bets

In related news, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $262.00, for a total value of $1,312,096.00. Following the sale, the vice president directly owned 10,710 shares in the company, valued at $2,806,020. The trade was a 31.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Renato Tamaro sold 5,036 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the transaction, the vice president directly owned 5,695 shares in the company, valued at $1,466,747.25. This represents a 46.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 25,044 shares of company stock worth $6,586,218. Company insiders own 1.07% of the company’s stock.

Institutional Investors Weigh In On STERIS

A number of hedge funds and other institutional investors have recently bought and sold shares of STE. Geneos Wealth Management Inc. grew its stake in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Advisory Services Network LLC purchased a new stake in STERIS during the third quarter worth about $68,000. MUFG Securities EMEA plc acquired a new position in STERIS during the second quarter worth about $69,000. Brown Brothers Harriman & Co. grew its position in STERIS by 51.3% during the third quarter. Brown Brothers Harriman & Co. now owns 528 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 179 shares during the period. Finally, Peapack Gladstone Financial Corp purchased a new position in STERIS in the second quarter valued at about $200,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.